Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07346859RecruitingPhase 3
Study of BP-SCIG 20% for primary immune deficiency
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
CherkasyAges birth+ - NCT07347860RecruitingEarly Phase 1
Study of A-319 for active rheumatoid arthritis
This trial tests a new drug called A-319 for people with active rheumatoid arthritis (RA) that hasn't improved enough after trying other treatments. The goal is to see if A-319 can reduce joint pain, swelling, and inflammation.
Wuhan, HubeiAges 18–70 - NCT07348055RecruitingPhase 1/Phase 2
A study of GR1803 for lupus
This trial tests a new drug called GR1803 for people with systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation. It may help reduce disease activity when standard treatments haven't worked well enough.
Wuhan, HubeiAges 18–60 - NCT07348302RecruitingPhase 3
Allergy tablet for dust mite rhinitis and asthma
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
Nueve de Julio, Buenos AiresAges 12–65 - NCT07348432Recruiting
Insulin delivery and eating behaviors in type 1 diabetes
This study looks at how different insulin delivery methods (like injections or pumps) affect eating behaviors in people with type 1 diabetes. By joining, you may help researchers learn how to improve care and quality of life.
Montreal, QuebecAges 12 years+ - NCT07348783Recruiting
Yoga for chronic migraine and cluster headache
This study tests whether yoga-based movements can help reduce headache frequency and improve well-being in people with chronic migraine or cluster headache. You would follow online or in-person yoga instructions at home for several weeks, wear an activity tracker, and provide blood samples.
HuddingeAges 18–65 - NCT07349212RecruitingPhase 1/Phase 2
Study of UKK-0018 for peanut allergy treatment
This trial tests a new immunotherapy called UKK-0018 to treat peanut allergies in adults. The goal is to help your body become less sensitive to peanuts over time.
Camperdown, New South WalesAges 18–55 - NCT07351916Recruiting
Asthma remission study for mild-to-moderate asthma
This study looks at whether adults with mild-to-moderate asthma can achieve remission. Remission means your asthma symptoms go away or become very well controlled. You will need to do breathing tests to take part.
Pathum Thani, Changwat Pathum ThaniAges 18 years+ - NCT07352332Recruiting
Immune study of a new treatment for hard-to-treat lupus in children
This study looks at how a treatment called CD3xCD19 BiTE affects the immune system of children with lupus that hasn't gotten better with standard medicines. It uses leftover blood samples to learn more about why some children don't respond to usual treatments.
HangzhouAges 5 years+ - NCT07352813Recruiting
Comparing numbing methods for kids with MIH teeth
This study tests two ways to numb teeth—in the bone or in the gum—to see which works better for children with weak enamel on their back teeth and front teeth. It may help find a pain-free way to treat these teeth.
AnkaraAges 6–12 - NCT07353216Recruiting
Testing ofatumumab for relapsing multiple sclerosis
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Guangzhou, GuangdongAges 18 years+ - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07354932RecruitingPhase 2
Testing SHR-2173 for IgA Nephropathy
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
Guangzhou, GuangdongAges 18 years+ - NCT07355387Recruiting
Home-based balance training for multiple sclerosis
This study tests a 12-week home-based balance training program for people with multiple sclerosis. Sessions are done online with a helper present, and the goal is to improve walking and reduce fall risk.
Chicago, IllinoisAges 40–90 - NCT07355699RecruitingPhase 4
Orelabrutinib for untreated marginal zone lymphoma
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
BeijingAges 18 years+ - NCT07356089Recruiting
Twiist insulin pump study for type 1 diabetes
This study follows people with type 1 diabetes who are already using the Twiist automated insulin delivery system. Researchers will ask you to complete surveys and share data for 12 months to check how well the system works in everyday life.
Tampa, FloridaAges 6 years+ - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07356310Recruiting
Body scan and breathing test for airway health
This trial uses a special breathing test to measure how your airways react. It helps doctors understand airway tone and reactivity, which may relate to conditions like asthma.
Rochester, New YorkAges 18 years+ - NCT07358364Recruiting
Remibrutinib in real-world chronic hives
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
Kirksville, MissouriAges 18 years+ - NCT07358156RecruitingPhase 1
Comparing a new dupilumab medicine to Dupixent in healthy adults
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
Berlin, State of BerlinAges 18–55 - NCT07358780Recruiting
Remibrutinib study for chronic hives
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
Kirksville, MissouriAges 18–100 - NCT07359183Recruiting
Long-term follow-up of kids who had oral immunotherapy for allergies
This study checks on children and young people 5 to 15 years after they finished an 18-month oral immunotherapy treatment for peanut, egg, or milk allergy. It helps researchers understand how their allergies and health are doing over the long term.
Parkville, VictoriaAges Any age - NCT07359430Recruiting
Deep phenotyping of chronic inducible urticaria
This study aims to better understand inducible urticaria (hives triggered by cold, pressure, or friction) and chronic spontaneous urticaria. Researchers will use skin tests to measure how different triggers affect your skin in detail.
Leiden, South HollandAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.